Vima Therapeutics is a technology company.
Vima Therapeutics has raised $60.0M across 1 funding round.
Vima Therapeutics has raised $60.0M in total across 1 funding round.
Vima Therapeutics has raised $60.0M in total across 1 funding round.
Vima Therapeutics's investors include Acorn Bioventures, Atlas Venture, OrbiMed.
Vima Therapeutics is a clinical-stage biotechnology company developing VIM0423, a potential first-in-class oral therapy targeting the root cause of dystonia and related movement disorders in the central nervous system.[1][2][3][4] It serves patients with these chronic conditions, which lack therapies addressing underlying causes, by advancing an oral treatment currently in Phase 1 trials with Phase 2 planned for Q4 2025; the company launched in May 2025 with a $60M Series A led by Atlas Venture, plus Access Industries and Canaan.[2][4]
Headquartered in Cambridge, Massachusetts, Vima focuses on improving patient movement control through innovative, patient-centered drug development led by movement disorder experts.[3][4][5]
Vima Therapeutics emerged from Atlas Venture's incubator as a seed investment, founded by physicians and scientists with deep expertise in movement disorders, including CEO Bernard Ravina, MD, MS, a neurologist with over 25 years in drug development across government, academia, industry, Biogen, Voyager Therapeutics, and Praxis Medicines.[2][4][5] David Grayzel, MD, partner at Atlas Venture, co-founded and chairs the board, emphasizing a singular focus on transforming dystonia patient lives from inception.[2][4]
The company launched publicly on May 29, 2025, with its $60M Series A, immediately advancing VIM0423 into Phase 1 clinical trials under leadership like head of R&D Judith Dunn.[2][4] This marked a pivotal shift from incubation to clinical-stage operations targeting unmet needs in oral therapies for movement disorders.[1][2]
Vima rides the wave of precision neurology and CNS drug innovation, targeting dystonia—a market with high unmet needs amid growing demand for oral, mechanism-based therapies over injectables.[1][2][4] Timing aligns with advances in muscarinic receptor targeting and biotech funding resurgence, enabling quick clinic entry via incubator models like Atlas Venture's.[2][4]
Market forces favor Vima: rising awareness of movement disorders, aging populations increasing prevalence, and investor interest in high-impact rare diseases with large addressable markets.[1][2] It influences the ecosystem by pioneering oral options, potentially accelerating similar CNS programs and validating VC-backed biotech launches.[3][4]
Vima is poised for Phase 2 initiation in Q4 2025, with potential Phase 3 and partnership opportunities if VIM0423 demonstrates efficacy in dystonia control.[2][4] Trends like AI-driven drug discovery and CNS breakthroughs will shape its path, possibly expanding to related disorders amid competition from similar biotechs.[1][2]
Its influence may grow by proving oral therapies viable for movement disorders, drawing more capital to the space and redefining patient standards—echoing its launch promise to change dystonia lives through root-cause innovation.[2][4]
Vima Therapeutics has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $60.0M Series A | Acorn Bioventures, Atlas Venture, OrbiMed |